Web Desc
Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies
joint with Purinergic Signaling
Organizer(s): Barbara Seliger, Jerome Galon and Francesco M. Marincola
Date: January 24 - 28, 2016
Location: Fairmont Hotel Vancouver, Vancouver, BC, Canada
Sponsored by BioLegend, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Merck & Co., Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.
Summary of Meeting:
This meeting focuses on immune escape mechanisms, immune tolerance, the role of immune effector and suppressor cells as well as the tumor microenvironment in this context, and the modulation of these different processes. In addition, the modes and efficacy of different cancer immunotherapeutic strategies and targeted therapies alone and in combination as well as their influence on the immune escape and immune suppressive activity will be an important topic. This meeting is expected to attract a broad range of scientists (e.g., biologists, biochemists, immunologists, cancer researchers) and clinicians (oncologists, pathologists, radiologists) and will bridge basic, translational and clinical research. The speakers invited represent basic researchers, clinicians and employees of the pharmaceutical industry. There will be a strong clinical focus to the program, in particular regarding different therapeutic strategies including cancer immunotherapy and targeted therapies, which have recently been successfully implemented for the therapy of many cancers including chronic myeloid leukemia, breast carcinoma, non-small lung carcinoma, colorectal cancer, kidney cancer and melanoma.
Scholarship Deadline: September 29 2015
Discounted Abstract Deadline: September 29 2015
Abstract Deadline: October 29 2015
Discounted Registration Deadline: November 24 2015
Keystone Symposia thanks our Sponsor(s) for generously supporting this meeting:
BioLegend, Inc.Genentech, Inc.Genmab A/SImmunoGen, Inc.Incyte CorporationInfinity Pharmaceuticals, Inc.Merck & Co., Inc.Mersana TherapeuticsMorphoSys AGPfizer Inc.Regeneron Pharmaceuticals, Inc.Sanofi USShire Human Genetic TherapiesThermo Fisher Scientific Inc.
We gratefully acknowledge additional support for this conference from:
Bio-TechneCharles River LaboratorieseBioscience, an Affymetrix companyNanoString Technologies
We gratefully acknowledge additional in-kind support for this conference from those foregoing speaker expense reimbursements:

Juno Therapeutics
We appreciate the organizations that provide Keystone Symposia with additional support, such as marketing and advertising:

Click here to view more of these organizations
Special thanks to the following for their support of Keystone Symposia initiatives to increase participation at this meeting by scientists from underrepresented backgrounds:

Click here to view more of these organizations

Program

Sunday, January 24 | 4:00PM - 8:00PM
Arrival and Registration
Room: British/Columbia Foyer


Sunday, January 24 | 6:00PM - 8:00PM
Welcome Mixer
Room: British/Columbia Foyer
No registration fees are used to fund alcohol served at this function.

Monday, January 25 | 7:30AM - 8:30AM
Breakfast
Room: Pacific Ballroom


Monday, January 25 | 8:30AM - 10:00AM
Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keyn
ote Address (Joint)
Room: British/Columbia Ballroom

Speaker 1 of 4
* Barbara Seliger, Martin Luther University, Germany

Monday, January 25 | 8:30AM - 10:00AM
Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keyn
ote Address (Joint)
Room: British/Columbia Ballroom

Speaker 2 of 4
* Joel Linden, La Jolla Institute for Allergy and Immunology, USA

Monday, January 25 | 8:30AM - 10:00AM
Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keyn
ote Address (Joint)
Room: British/Columbia Ballroom

Speaker 3 of 4
Simon C. Robson, Beth Israel Deaconess Medical Center, USA
Purinergic Signaling and Conditioning of Inflammatory Responses in Clinical Disease

Monday, January 25 | 8:30AM - 10:00AM
Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keyn
ote Address (Joint)
Room: British/Columbia Ballroom

Speaker 4 of 4
Robert D. Schreiber, Washington University School of Medicine, USA
Personalizing Cancer Immunotherapy

Monday, January 25 | 10:00AM - 10:20AM
Coffee Break
Room: British/Columbia Foyer


Monday, January 25 | 10:20AM - 12:15PM
Tumor Microenvironment and Effector Cells
Room: Columbia Ballroom

Speaker 1 of 5
* Jerome Galon, INSERM UMRS1138, Cordeliers Research Center, France

Monday, January 25 | 10:20AM - 12:15PM
Tumor Microenvironment and Effector Cells
Room: Columbia Ballroom

Speaker 2 of 5
Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany
Adoptive T Cell Therapy

Monday, January 25 | 10:20AM - 12:15PM
Tumor Microenvironment and Effector Cells
Room: Columbia Ballroom

Speaker 3 of 5
Barbara Seliger, Martin Luther University, Germany
Escape of Tumors from Immune Cell Recognition by Modulating MHC Class I Antigen Processing Components

Monday, January 25 | 10:20AM - 12:15PM
Tumor Microenvironment and Effector Cells
Room: Columbia Ballroom

Speaker 4 of 5
Fathia Mami-Chouaib, Institut Gustave Roussy, France
Paradoxical Role of TGF-beta in Promoting CTL Effector Functions within Epithelial Tumor Microenvironment by Triggering CD103 Integrin Expression and Signaling

Monday, January 25 | 10:20AM - 12:15PM
Tumor Microenvironment and Effector Cells
Room: Columbia Ballroom

Speaker 5 of 5
David C. Clever, National Institutes of Health, USA
Short Talk: Inhibition of T Cell Oxygen Sensing Promotes Pulmonary Effector Responses and Limits Tumor Metastasis

Monday, January 25 | 10:20AM - 12:30PM
Purine Release
This session is from Purinergic Signaling
Room: British Ballroom
Mechanisms of purine release from cells.
Speaker 1 of 5
* Gerhard Dahl, University of Miami, USA
ATP Release through Pannexon Channels.


Monday, January 25 | 10:20AM - 12:30PM
Purine Release
This session is from Purinergic Signaling
Room: British Ballroom
Mechanisms of purine release from cells.
Speaker 2 of 5
Christa E. Müller, Universität Bonn, Germany
Medicinal Chemistry of Purinergic Signalling


Monday, January 25 | 10:20AM - 12:30PM
Purine Release
This session is from Purinergic Signaling
Room: British Ballroom
Mechanisms of purine release from cells.
Speaker 3 of 5
Leon J. DeLalio, University of Virginia, USA
Short Talk: Localization of Panx1 to Caveolae Facilitates ATP Release in the Vasculature


Monday, January 25 | 10:20AM - 12:30PM
Purine Release
This session is from Purinergic Signaling
Room: British Ballroom
Mechanisms of purine release from cells.
Speaker 4 of 5
Marta Radwan, University of Bath, UK
Short Talk: The Mouse Pannexin1-P2X7 Receptor Interactome


Monday, January 25 | 10:20AM - 12:30PM
Purine Release
This session is from Purinergic Signaling
Room: British Ballroom
Mechanisms of purine release from cells.
Speaker 5 of 5
Francesco Di Virgilio, University of Ferrara, Italy
ATP: A Novel Constituent of the Tumor Microenvironment affecting Tumor
Growth and Metastatic Spreading


Monday, January 25 | 12:15PM - 1:00PM
Poster Setup
Room: Pacific Ballroom


Monday, January 25 | 12:15PM - 2:30PM
On Own for Lunch


Monday, January 25 | 1:00PM - 10:00PM
Poster Viewing
Room: Pacific Ballroom


Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 1 of 8
* Jerome Galon, INSERM UMRS1138, Cordeliers Research Center, France

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 2 of 8
Matthew Coelho, University College London - The Francis Crick Institute, UK
Oncogenic RAS Signaling Promotes Tumor Immunoresistance by Stabilizing PD-L1 mRNA

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 3 of 8
Daniel Corey, Stanford University, USA
Reverse Engineering B. Schlosseri Developmental-regulated Cell Death Programs for Cancer Immunotherapy

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 4 of 8
Mirjana Efremova, Medical University of Innsbruck, Austria
Modeling Immunoediting of the Tumor during Progression

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 5 of 8
Mirjam H.M. Heemskerk, Leiden University Medical Center, Netherlands
TCR Gene Therapy Targeting the Intracellular Transcription Factor Bob1 for the Treatment of Multiple Myeloma

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 6 of 8
Nikhil S. Joshi, Yale University School of Medicine, USA
Investigating Endogenous Anti-tumor T Cell Responses in Native Tumor Microenvironments

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 7 of 8
Rachel Yamin, Hebrew University, Israel
Profiling of Ubiquitin Modifications in NK Cell Activation

Monday, January 25 | 2:30PM - 4:30PM
Workshop
Room: Columbia Ballroom

Speaker 8 of 8
Iryna Saranchova, University of British Columbia, Canada
Molecular Studies on the Primary to Metastatic Transition

Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 10
* Brant Isakson, University of Virginia, USA


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 10
* Gennady G. Yegutkin, University of Turku, Finland


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 10
Alexander S. Keller, University of Virginia, USA
Expression of Pannexin Isoforms in Mouse Erythrocytes


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 10
Miranda E. Good, University of Virginia, USA
Smooth Muscle Cell Pannexin1 can Regulate Myogenic Reactivity in Cerebral Arteries


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 10
Kishio Furuya, Nagoya University, Japan
Stretch Induced ATP Release via Hemichannels Accelerates Wound Closure in Keratinocyte by Ca2+ Influx from TRPC6


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 6 of 10
Juan Pablo Huidobro-Toro, Universidad de Santiago de Chile, Chile
A Potassium Rich Diet Increased Mechanically Evoked ATP Release from Rat Mesenteric Endothelial Cells; Clinical Implications


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 7 of 10
Christian Renn, University of Bonn, Germany
Comparison of ecto-5‘-nucleotidase (CD73) Assays for the Identification and Characterization of Inhibitors


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 8 of 10
Florian Wirsdörfer, University Hospital Essen, Germany
Role of CD73 and Extracellular Adenosine in Radiation-Induced Lung Fibrosis


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 9 of 10
Gilles Kauffenstein, Angers University, France
Vascular Changes in Pseudoxanthoma Elasticum - Potential Link to Extracellular Purine Metabolism


Monday, January 25 | 2:30PM - 4:30PM
Workshop 1: ATP Release and Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 10 of 10
Maria Serena Longhi, Beth Israel Deaconess Medical Center, USA
Aberrant Regulation of CD39 Expression by Th17 Cells in Inflammatory Bowel Disease


Monday, January 25 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Monday, January 25 | 5:00PM - 7:00PM
Immune Signature and Biomarkers
Room: Columbia Ballroom

Speaker 1 of 5
* Barbara Seliger, Martin Luther University, Germany

Monday, January 25 | 5:00PM - 7:00PM
Immune Signature and Biomarkers
Room: Columbia Ballroom

Speaker 2 of 5
Jerome Galon, INSERM UMRS1138, Cordeliers Research Center, France
Importance of the Immune Infiltration and Cancer Classification

Monday, January 25 | 5:00PM - 7:00PM
Immune Signature and Biomarkers
Room: Columbia Ballroom

Speaker 3 of 5
Francesco M. Marincola, Sidra Medical and Research Center, Qatar
A Panoramic View of Tumor Rejection Induced by Immune Therapy

Monday, January 25 | 5:00PM - 7:00PM
Immune Signature and Biomarkers
Room: Columbia Ballroom

Speaker 4 of 5
Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T Cell Recognition and Tumor Resistance in Human Cancer

Monday, January 25 | 5:00PM - 7:00PM
Immune Signature and Biomarkers
Room: Columbia Ballroom

Speaker 5 of 5
Daniela Schmid, Dana-Farber Cancer Institute, USA
Short Talk: T Cell-Targeted Nanoparticles for Delivery of Immunomodulatory Molecules

Monday, January 25 | 5:00PM - 7:00PM
Purine Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 4
* Norbert Sträter, University of Leipzig, Germany
Structure and Function of CD39 and CD73 in Purinergic Signalling


Monday, January 25 | 5:00PM - 7:00PM
Purine Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 4
* Elizabeth Hartland, University of Melbourne, Australia
Microbial NTPDases and their role during infection


Monday, January 25 | 5:00PM - 7:00PM
Purine Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 4
Ridong Chen, APT Therapeutics, Inc., USA
Human Apyrase as a Paradigm-shifting Therapy for Cardiovascular Diseases with Undetectable Bleeding Risk


Monday, January 25 | 5:00PM - 7:00PM
Purine Metabolism
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 4
Cynthia St. Hilaire, University of Pittsburgh, USA
Short Talk: In Vivo Disease Modeling Using Patient-Derived iPSCs: CD73-Deficiency Promotes Osteogenic Differentiation and Calcification


Monday, January 25 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom
No registration fees are used to fund alcohol served at this function.

Monday, January 25 | 7:30PM - 10:00PM
Poster Session 1
Room: Pacific Ballroom


Tuesday, January 26 | 7:30AM - 8:30AM
Breakfast
Room: Pacific Ballroom


Tuesday, January 26 | 8:00AM - 8:30AM
Poster Setup
Room: Pacific Ballroom


Tuesday, January 26 | 8:30AM - 5:00PM
Poster Viewing
Room: Pacific Ballroom


Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 1 of 6
* Francesco M. Marincola, Sidra Medical and Research Center, Qatar

Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 2 of 6
James P. Allison, University of Texas MD Anderson Cancer Center, USA
Tumor Targeting using Checkpoint Antibodies

Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 3 of 6
Carlo M. Croce, Ohio State University, USA
Causes and Consequences of microRNA Dysregulation in Cancer

Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 4 of 6
Ofer Mandelboim, Hebrew University, Israel
Importance of Bacteria in Modulating NK Cell Response against Tumors

Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 5 of 6
Francesca Finotello, Biocenter, Medical University of Innsbruck, Austria
Short Talk: Quantification of Tumor-Infiltrating Lymphocyte Subpopulations using Imaging and Sequencing Data

Tuesday, January 26 | 8:30AM - 11:30AM
Systems Biology and Dysregulation in Cancer
Room: Columbia Ballroom

Speaker 6 of 6
Spencer C. Wei, Spotlight Therapeutics, USA
Short Talk: High-Dimensional Cytometry Reveals Novel T cell Populations that Arise in the Absence of CTLA-4

Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 1 of 6
* Mark Yeager, University of Virginia School of Medicine, USA
Structural Biology of Adenosine Receptor G-Protein Complexes


Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 2 of 6
Stefano Moro, University of Padova, Italy
Short Talk: Could Adenosine Engage its Receptors with an Alternative 1:1 Stoichiometry? New Insights from Supervised Molecular Dynamics (SuMD) Simulations


Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 3 of 6
Ruben Abagyan, University of California, San Diego, USA
Modeling and Structure Based Discovery of Allosteric Modulators


Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 4 of 6
Edward P. Amento, Molecular Medicine Research Institute, USA
Short Talk: Positive Allosteric Modulation of the Adenosine A2a Receptor Alleviates PMA-Induced Acute Contact Dermatitis in Mice


Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 5 of 6
* Kodi S. Ravichandran, University of Virginia, USA
Don't Let Death Do Us Part: Pannexin Channels in Communication between Apoptotic Cells and Phagocytes


Tuesday, January 26 | 8:30AM - 11:45AM
Adenosine and P2Y Structure and Medicinal Chemistry
This session is from Purinergic Signaling
Room: British Ballroom
New developments in adenosine receptor signaling.
Speaker 6 of 6
* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA
Structure-Based Design of P2Y Receptor Ligands


Tuesday, January 26 | 9:50AM - 10:10AM
Coffee Break
Room: British/Columbia Foyer


Tuesday, January 26 | 11:30AM - 12:30PM
Lunch
Room: Pacific Ballroom


Tuesday, January 26 | 12:00PM - 2:30PM
Poster Session 2
Room: Pacific Ballroom


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 9
* Silvia Deaglio, University of Turin, Italy


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 9
* Simon C. Robson, Beth Israel Deaconess Medical Center, USA


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 9
Sara Serra, University of Turin and Human Genetics Foundation, Italy
Adenosine Signaling Mediates Hypoxic Responses in the Chronic Lymphocytic Leukemia (CLL) Microenvironment


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 9
Bruce Cronstein, New York University, USA
Ticagrelor Inhibits Spread of Multiple Myeloma to Bone


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 9
Jessica Lynn Bowser, University of Texas MD Anderson Cancer Center, USA
CD73 Mediates Epithelial Integrity in Endometrial Carcinoma: Is Protecting the Barrier Promoting Tumor Immunosuppression


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 6 of 9
Amanda S. MacLeod, Duke University, USA
IL-27-Inducible ENTPD1 Suppresses Protective Skin-Resident Immunity upon UV Damage and Inhibits DNA Repair


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 7 of 9
Odd Lilleng Gammelgaard, University of Southern Denmark, Denmark
Dual Epitope Targeting of CD73 Exhibits Potent Anti-Cancer Activity


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 8 of 9
Daniela Sauma, Universidad de Chile, Chile
CD73-Mediated Adenosine Production Promotes Stem Cell-Like Properties in Mouse Tc17 Cells


Tuesday, January 26 | 2:30PM - 4:30PM
Workshop 2: Purinergic Receptors and Cancer
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 9 of 9
Miki Kamiyama, University of Tokyo, Japan
ASK1 Regulates Tumor Lung Metastasis and Platelet Functions through ADP Signaling


Tuesday, January 26 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Tuesday, January 26 | 5:00PM - 7:00PM
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Ther
apy

Room: Columbia Ballroom

Speaker 1 of 5
* Thomas Blankenstein, Max Delbruck Center for Molecular Medicine, Germany

Tuesday, January 26 | 5:00PM - 7:00PM
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Ther
apy

Room: Columbia Ballroom

Speaker 2 of 5
Nicholas P. Restifo, Lyell, USA
Curative Immunotherapy Using CAR- and TCR-Based T Cells

Tuesday, January 26 | 5:00PM - 7:00PM
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Ther
apy

Room: Columbia Ballroom

Speaker 3 of 5
Gerold Schuler, University Hospital of Erlangen, Germany
Monocyte-Derived Dendritic Cells as Vaccines: Beyond Simple Induction of T Cells

Tuesday, January 26 | 5:00PM - 7:00PM
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Ther
apy

Room: Columbia Ballroom

Speaker 4 of 5
Ronald Levy, Stanford University, USA
Targeting the Immune System while Targeting the Cancer Customized vs. Off-the-Shelf Therapies

Tuesday, January 26 | 5:00PM - 7:00PM
Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Ther
apy

Room: Columbia Ballroom

Speaker 5 of 5
Karl-Johan Malmberg, Radiumhospitalet, Norway
Short Talk: Critical Role of CD2 Co-Stimulation in Adaptive NK Cell Responses Revealed in NKG2C-Deficient Humans

Tuesday, January 26 | 5:00PM - 7:00PM
Drugs Targeting Adenosine Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 5
* Bruce Cronstein, New York University, USA


Tuesday, January 26 | 5:00PM - 7:00PM
Drugs Targeting Adenosine Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 5
Tomyuki Kanda, Kyowa Hakko Kirin Co., Ltd., Japan
Adenosine A2A Receptor as Therapeutic Target for Parkinson's and Neurodegeneration


Tuesday, January 26 | 5:00PM - 7:00PM
Drugs Targeting Adenosine Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 5
Joel Linden, La Jolla Institute for Allergy and Immunology, USA
Inhibition of Sterile Inflammation by Adenosine


Tuesday, January 26 | 5:00PM - 7:00PM
Drugs Targeting Adenosine Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 5
* Pnina Fishman, Can-Fite BioPharma Ltd., Israel
Utilizing the A3 Adenosine Receptor as a Target to Combat Cancer: From Lab to Labeling


Tuesday, January 26 | 5:00PM - 7:00PM
Drugs Targeting Adenosine Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 5
† Carmen Corciulo, New York University Medical Center, USA
Short Talk: Adenosine A2A Receptor, But Not A2B Receptor, Deletion Leads to Development of Osteoarthritis (OA) in Mice and Administration of a Liposomal Suspension of Adenosine Prevents/Treats Osteoarthritis in Rats


Tuesday, January 26 | 7:00PM - 7:00PM
On Own for Dinner


Wednesday, January 27 | 7:30AM - 8:30AM
Breakfast
Room: Pacific Ballroom


Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 1 of 6
* Rolf Kiessling, Karolinska Institute, Sweden

Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 2 of 6
Joel Le Maoult, Institut Universitaire d'Hématologie, France
Role of HLA-G in Human Tumors

Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 3 of 6
Sandra Demaria, Weill Cornell Medical College, USA
Harnessing Radiotherapy to Overcome Tumor Resistance to Immunotherapy

Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 4 of 6
Sjoerd H. van der Burg, Leiden University Medical Center, Netherlands
HLA-E in Cancer: From Immune Escape to Therapeutic Target?

Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 5 of 6
Erik Thiele Orberg, University Clinic Rechts der Isar, Technical University Munich, Germany
Short Talk: The Myeloid Immune Signature of Enterotoxigenic Bacteroides fragilis-induced Murine Colon Tumorigenesis

Wednesday, January 27 | 8:30AM - 11:30AM
Immune Suppression and the Role of Paracrine Factors in Modu
lating Immune Suppression

Room: Columbia Ballroom

Speaker 6 of 6
Byron Kwan, Massachusetts Institute of Technology, USA
Short Talk: Integrin-targeted Combination Immunotherapy Improves Survival in a Broad Spectrum of Tumor Types

Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 7
* Joel Linden, La Jolla Institute for Allergy and Immunology, USA


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 7
Gennady G. Yegutkin, University of Turku, Finland
Cellular Purine Homeostasis as a Complex and Coordinated Network Controlling Tumor Invasion and Migration


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 7
John Stagg, University of Montréal, Canada
CD73-mediated Adenosine Signaling in Human Cancers


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 7
* Michail Sitkovsky, Northeastern University, USA
Conceptually Novel “Anti-Hypoxia-A2A-Adenosinergic” Checkpoint Inhibitors to Improve Immunotherapies and Chemotherapies of Cancer


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 7
Caglar Cekic, Bilkent University, Turkey
Adenosine Regulation of Myeloid Cells in Solid Tumors


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 6 of 7
Erik Wennerberg, Weill Cornell Medical College, USA
Short Talk: Adenosine Regulates Radiation Therapy-Induced Anti-Tumor Immunity


Wednesday, January 27 | 8:30AM - 11:45AM
Cancer Immunotherapy I
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 7 of 7
Arabella Young, QIMR Berghofer Medical Research Institute, Australia
Short Talk: Co-inhibition of Adenosine Generation and Signaling Improves Anti-Tumour Immune Responses


Wednesday, January 27 | 9:50AM - 10:10AM
Coffee Break
Room: British/Columbia Foyer


Wednesday, January 27 | 11:30AM - 1:00PM
Poster Setup
Room: Pacific Ballroom


Wednesday, January 27 | 11:30AM - 5:00PM
On Own for Lunch


Wednesday, January 27 | 1:00PM - 10:00PM
Poster Viewing
Room: Pacific Ballroom


Wednesday, January 27 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Wednesday, January 27 | 5:00PM - 7:00PM
Novel Immunotherapeutic Approaches and Antibody Therapies
Room: Columbia Ballroom

Speaker 1 of 4
* Michele Maio, University Hospital of Siena, Italy

Wednesday, January 27 | 5:00PM - 7:00PM
Novel Immunotherapeutic Approaches and Antibody Therapies
Room: Columbia Ballroom

Speaker 2 of 4
Gregory Lawrence Beatty, University of Pennsylvania, USA
Activating Innate and Adaptive Immunity by CD40 Agonists

Wednesday, January 27 | 5:00PM - 7:00PM
Novel Immunotherapeutic Approaches and Antibody Therapies
Room: Columbia Ballroom

Speaker 3 of 4
Nils Lonberg, Canaan Partners, USA
Immune Checkpoints and Combination Therapy

Wednesday, January 27 | 5:00PM - 7:00PM
Novel Immunotherapeutic Approaches and Antibody Therapies
Room: Columbia Ballroom

Speaker 4 of 4
Susanne Steggerda, Calithera Biosciences, Inc., USA
Short Talk: Arginase Inhibitor CB-1158 is a Novel Immuno-Oncology Agent that Targets Tumor-Infiltrating Suppressive Myeloid Cells

Wednesday, January 27 | 5:00PM - 7:00PM
Cancer Immunotherapy II
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 5
* John Stagg, University of Montréal, Canada


Wednesday, January 27 | 5:00PM - 7:00PM
Cancer Immunotherapy II
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 5
Kris F. Sachsenmeier, MedImmune LLC, USA
MEDI9447: Targeting CD73 in the Tumor Microenvironment


Wednesday, January 27 | 5:00PM - 7:00PM
Cancer Immunotherapy II
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 5
Phillip K. Darcy, Peter MacCallum Cancer Centre, Australia
Enhancing Adoptive Cellular Therapy by Targeting Tumor-Induced Immunosuppression


Wednesday, January 27 | 5:00PM - 7:00PM
Cancer Immunotherapy II
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 5
* Mark J. Smyth, QIMR Berghofer Medical Research Institute, Australia
Strategies for Combination Cancer Immunotherapies that Target Adenosine


Wednesday, January 27 | 5:00PM - 7:00PM
Cancer Immunotherapy II
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 5
Dora Hammerl, Erasmus Medical Center, Netherlands
Short Talk: Intratumeral Injection of Microparticles Containing the A2A Receptor Antagonist SCH58261 Slow Tumor Growth and Metastasis More Effectively than Systemic Drug Administration


Wednesday, January 27 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom
No registration fees are used to fund alcohol served at this function.

Wednesday, January 27 | 7:30PM - 10:00PM
Poster Session 3
Room: Pacific Ballroom


Thursday, January 28 | 7:30AM - 8:30AM
Breakfast
Room: Pacific Ballroom


Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 1 of 6
Thomas Gajewski, University of Chicago, USA
Molecular Mechanisms of the T Cell-Inflamed Tumor Microenvironment: Implications for Immunotherapy

Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 2 of 6
Rolf Kiessling, Karolinska Institute, Sweden
Counteracting Tumor-Induced Immune Suppression by Checkpoint Blockade and Inhibitors of CSF-R1

Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 3 of 6
David H. Munn, Georgia Regents University, USA
IDO, PTEN and Activated Tregs in the Tumor Microenvironment

Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 4 of 6
Robert Leone, Johns Hopkins University School of Medicine, USA
Role of Metabolic Changes on the Immune Response

Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 5 of 6
Robbert M. Spaapen, Sanquin Research, Netherlands
Short Talk: Intramolecular MHC Class I Regulation Affects Functional Antigen Presentation

Thursday, January 28 | 8:30AM - 11:45AM
Immune Escape Mechanisms by Immune Suppressive Cells/Factors
Room: Columbia Ballroom

Speaker 6 of 6
Anushka Dongre, Whitehead Institute for Biomedical Research, USA
Short Talk: Understanding the Contribution of the Epithelial to Mesenchymal Transition (EMT) to Immuno-suppression in Breast Carcinomas

Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 6
* Kazuhide Inoue, Kyushu University, Japan
Purinergic Regulation of Microglia in Neuropathic Pain


Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 6
* Maria P. Abbracchio, University of Milan, Italy
Purinergic Regulation of Oligodendrocyte Precursor Cells and Myelination


Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 6
Masahiro Mishina, Nippon Medical School, Japan
Brain Imaging of Adenosine Receptors


Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 6
Francisco J. Quintana, Harvard Medical School, USA
Control of Autoimmune Inflammation by CD39 (ENTPD1)


Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 6
Mallikarjunarao Ganesana, University of Virginia, USA
Short Talk: Increase of Transient Adenosine Release Frequency from Ischemic Brain


Thursday, January 28 | 8:30AM - 11:45AM
Purinergic Signaling in the CNS
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 6 of 6
Catia Lambertucci, University of Camerino, Italy
Short Talk: Partial Agonists of A1 Adenosine Receptors as Neuroprotective Agents


Thursday, January 28 | 9:50AM - 10:10AM
Coffee Break
Room: British/Columbia Foyer


Thursday, January 28 | 11:45AM - 5:00PM
On Own for Lunch


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 10
* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 10
* Christa E. Müller, Universität Bonn, Germany


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 10
Aranzazu M. Mediero, New York University School of Medicine, USA
Ticagrelor Regulates Osteoblast and Osteoclast Function and Promotes Bone Formation in Vivo via an Adenosine Dependent Mechanism


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 10
Guido Beldi, University of Bern, Switzerland
P2X1 Regulated IL-22 Secretion by Innate Lymphoid Cells is Required for Efficient Liver Regeneration


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 5 of 10
Stephanie Weinhausen, University of Bonn, Germany
Binding Site of the Allosteric P2X4 Receptor Modulator Ivermectin


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 6 of 10
Ronald Sluyter, University of Wollongong, Australia
P2X7 Receptor Activation Mediates Amyotrophic Lateral Sclerosis-Associated Mutant Superoxide Dismutase 1 Release from Murine Motor Neurons


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 7 of 10
Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Germany
Nanobodies That Block Gating of the P2X7 ion Channel Ameliorate Inflammation


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 8 of 10
Alicia Mathers, University of Pittsburgh, USA
Signaling Through the P2X7 Receptor Induces an Acute Psoriasis-Like Inflammatory Response in the Skin


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 9 of 10
Mabrouka Salem, Laval University, Canada
P2Y6 Receptor Deletion Exacerbates Intestinal Inflammation Through Th17 Recruitment


Thursday, January 28 | 2:30PM - 4:30PM
Workshop 3: P2 Purinergic Receptors as Drug Targets
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 10 of 10
Angela Schulz, University Leipzig, Medical Faculty, Germany
P2Y14 Influences Insulin Secretion


Thursday, January 28 | 4:30PM - 5:00PM
Coffee Available
Room: British/Columbia Foyer


Thursday, January 28 | 5:00PM - 6:45PM
Targeted Therapies and Combination Therapies
Room: Columbia Ballroom

Speaker 1 of 4
* Barbara Seliger, Martin Luther University, Germany

Thursday, January 28 | 5:00PM - 6:45PM
Targeted Therapies and Combination Therapies
Room: Columbia Ballroom

Speaker 2 of 4
Adrian Bot, Kite Pharma, Inc., USA
Optimizing the Translation of Genetically Programmed T Cells to Safe and Potent Therapies

Thursday, January 28 | 5:00PM - 6:45PM
Targeted Therapies and Combination Therapies
Room: Columbia Ballroom

Speaker 3 of 4
Leisha A. Emens, Johns Hopkins School of Medicine, USA
Enhancing Cancer Vaccine Activity with Tumor-Specific Monoclonal Antibodies

Thursday, January 28 | 5:00PM - 6:45PM
Targeted Therapies and Combination Therapies
Room: Columbia Ballroom

Speaker 4 of 4
Michele Maio, University Hospital of Siena, Italy
Sequential Therapy of Checkpoint Inhibitors with Targeted Therapies

Thursday, January 28 | 5:00PM - 6:45PM
P2 Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 4
* Friedrich Koch-Nolte, University Medical Center Hamburg-Eppendorf, Germany


Thursday, January 28 | 5:00PM - 6:45PM
P2 Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 2 of 4
* Rosaria Volpini, Università degli Studi di Camerino, Italy
P2 Receptor Ligands: Overview and Updates


Thursday, January 28 | 5:00PM - 6:45PM
P2 Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 3 of 4
Marco Cattaneo, Università degli Studi di Milano, Italy
P2Y12 Receptors: Structure and Function


Thursday, January 28 | 5:00PM - 6:45PM
P2 Receptors
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 4 of 4
Mufeng Li, NINDS, National Institutes of Health, USA
Structure and Gating Mechanisms of ATP Activated P2X Receptor Channels


Thursday, January 28 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions (Organizers)
Room: Columbia Ballroom


Thursday, January 28 | 6:45PM - 7:00PM
Meeting Wrap-Up: Outcomes and Future Directions
This session is from Purinergic Signaling
Room: British Ballroom

Speaker 1 of 1
* Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA


Thursday, January 28 | 7:00PM - 8:00PM
Social Hour with Lite Bites
Room: Pacific Ballroom
No registration fees are used to fund alcohol served at this function.

Thursday, January 28 | 8:00PM - 11:00PM
Entertainment
Room: Pacific Ballroom
Entertainment is not subsidized by conference registration fees nor any U.S. federal government grants. Funding for this expense is provided by other revenue sources.

Thursday, January 28 | 8:00PM - 11:00PM
Cash Bar
Room: Pacific Ballroom


Friday, January 29 | 10:25AM - 10:25AM
Departure


*Session Chair.